Společnost iRhythm Holdings odhalila únik dat po neoprávněném přístupu k aplikacím třetích stran; mohly být ohroženy zdravotní a osobní údaje pacientů. Počet dotčených osob nebyl zveřejněn.
NEWTOWN, Pa., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Edelson Lechtzin LLP, a national class action law firm, is investigating data privacy claims arising from a reported data breach at iRhythm Holdings, Inc. (NASDAQ: IRTC). Anyone who has received a data breach notice from iRhythm, or who believes their personal information may have been exposed, can request a free case evaluation.
iRhythm Holdings data breach — at a glance
Company: iRhythm Holdings, Inc. is a San Francisco-based heart-monitoring company and maker of the Zio cardiac monitoring platform, used by approximately 8 million patients in the U.S. and Europe.
Reported: iRhythm disclosed the incident to the U.S. Securities and Exchange Commission on a Form 8-K dated June 10, 2026, and, following its investigation, began notifying impacted individuals on October 2, 2026.
How it happened: An unauthorized party gained access to certain third-party-hosted business applications through social engineering; a threat actor then demanded payment not to disclose the data.
When: The unauthorized access was detected on or around June 8, 2026.
Who may be affected: Patients and others whose personal and protected health information iRhythm maintained and who received a notification.
Status: The total number of individuals affected has not been publicly confirmed; iRhythm has described the incident as material given the volume of data involved.
Cost to you: Nothing. Click here for a free evaluation. What Happened
On or around June 8, 2026, iRhythm detected unauthorized access to certain third-party-hosted business applications and activated its incident response plan. On June 9, 2026, a threat actor claimed to have obtained sensitive information — including patient protected health information — and demanded payment not to disclose it. iRhythm disclosed the incident to the SEC on June 10, 2026, as material given the volume of data involved, and, after completing its investigation, began notifying impacted individuals on October 2, 2026. The total number affected has not been publicly confirmed.
What Personal Information May Be at Risk
According to iRhythm, the information involved varied by individual and may include patient name; contact information (address, email, and phone number); iRhythm patient account number; device serial number; patient insurance number; date of service; and date of birth. iRhythm states it does not store individual financial account or payment card information and has no evidence that any information has been or will be used to commit identity theft.
Your Legal Options
Edelson Lechtzin LLP is investigating a potential class action on behalf of patients whose sensitive personal and health information may have been compromised. A successful case could recover compensation for losses such as lost time, out-of-pocket costs, and loss of privacy, and could push iRhythm to strengthen how it protects personal information. Anyone who received a breach notification may face an increased risk of identity theft and fraud and is encouraged to come forward. The firm will evaluate your rights and potential claims at no cost.
Recommended Steps to Protect Yourself
Preserve any breach notice you received, and monitor your account statements and credit reports for suspicious activity.Because health and insurance information may be involved, guard against medical identity theft by reviewing explanation-of-benefits statements for services you did not receive.Consider placing a fraud alert or security freeze with Equifax, Experian, and TransUnion, and request your free annual credit reports at annualcreditreport.com. Contact Us for a Free Case Evaluation
Speak confidentially with a data privacy attorney today: Marc Edelson, Esq., Edelson Lechtzin LLP, 411 S. State Street, Suite N-300, Newtown, PA 18940; Phone: 844-696-7492; Email: [email protected]; Web: www.edelson-law.com.
About Edelson Lechtzin LLP
Edelson Lechtzin LLP is a national class action law firm with offices in Pennsylvania and California. In addition to data breach litigation, the firm handles class and collective actions involving securities and investment fraud, federal antitrust violations, ERISA employee benefit plans, wage theft, and consumer fraud.
Legal Notice: This press release may be considered Attorney Advertising in some jurisdictions. Prior results do not guarantee a similar outcome. The data breach described above is based on iRhythm's public disclosures, including its Form 8-K and subsequent incident update; certain details, including the total number of individuals affected, remain unconfirmed.
iRhythm dokončila akvizici společnosti Vital Connect za 237,5 milionu USD v hotovosti a až 423 334 akcií. Očekává zrychlení růstu tržeb od roku 2027 a do roku 2027 cílí na 15% upravenou marži EBITDA.
What happened On October 5, 2026, iRhythm Holdings, Inc. (NASDAQ: IRTC) said it completed its previously announced acquisition of Vital Connect, Inc. The buyer was iRhythm Technologies, Inc., iRhythm's direct wholly owned subsidiary.
Vital Connect is now a wholly owned subsidiary of that unit and an indirect subsidiary of iRhythm Holdings, Inc. The purchase included $237.5 million in cash, subject to customary adjustments and funded from iRhythm's balance sheet, plus up to 423,334 shares at closing. iRhythm also provided $10.0 million of working capital funding to Vital Connect between signing and closing.
Key numbers Metric Latest Change Source Cash purchase consideration $237.5 million iRhythm press release Working capital funding $10.0 million iRhythm press release Shares issued at closing up to 423,334 shares iRhythm press release 2027 adjusted EBITDA margin target 15% iRhythm press release Read more: iRhythm (IRTC) stock analysis and investment case Why it matters OptimistFi's case is that iRhythm can create value if Zio stays a clinically trusted, reimbursed, end-to-end cardiac monitoring workflow that turns test volume into high gross profit and eventually durable GAAP profitability. The press release says the acquisition expands iRhythm's ambulatory cardiac monitoring capabilities, including mobile cardiac telemetry, and broadens the portfolio across ambulatory, inpatient and hospital-to-home care.
It also says the deal is expected to lift iRhythm's revenue growth rate starting in 2027 while keeping its 15% adjusted EBITDA margin target for 2027.
Vital Connect's platform offers up to 30-day patient monitoring, four-in-one functionality, flexible service models and live look-in. It can also monitor up to 11 physiological parameters. iRhythm said the combination is meant to serve different customer workflows and clinician and patient needs. The release says iRhythm's commercial scale, health system relationships, market access expertise and integrated clinical service capabilities are expected to speed Vital Connect's growth and widen customer access.
By OptimistFi's calculation, the $10.0 million working capital funding is about 4.2% of the $237.5 million cash purchase consideration. The cash payment is still the main part of the deal, while the equity piece can reach up to 423,334 shares. The release says the expected benefits depend on successful integration and cites risks including business disruption, reimbursement, competition or regulation, product delays, and loss of key employees, customers or partners.
Browse: stock research on every company OptimistFi covers
What's next iRhythm said it will provide updated 2026 financial guidance, including Vital Connect, during its third quarter earnings call on November 5, 2026. That update will be the next dated check on whether the deal changes the growth outlook while keeping the 15% adjusted EBITDA margin target in view.
More from OptimistFi IRTC stock: the iRhythm thesis, its status and the next test to watch United States Brent Oil Fund, LP (NYSE Arca: BNO) Tracks a Supply Gap Alpha Teknova, Inc. (NASDAQ: TKNO) Adds Regulatory Support for PluriFreeze Meta Platforms, Inc. (NASDAQ: META) Has a Conditional $18 Billion Bill Stock research on every company OptimistFi covers Latest stock research and investment-case updates OptimistFi: evidence-first equity research Sources SEC 8-K — Current report dated October 5, 2026. iRhythm press release — Press release announcing completion of the Vital Connect acquisition. Read the full OptimistFi thesis on iRhythm Holdings, Inc.: https://optimistfi.com/stocks/IRTC
See what would break the iRhythm Holdings, Inc. thesis and track it live on the OptimistFi Thesis-Break Engine.
Browse every company OptimistFi covers at optimistfi.com/stocks, or read the latest evidence-first research.
The full iRhythm Holdings, Inc. investment case, its status and the next test to watch live on the iRhythm Holdings, Inc. thesis page.
Originally published on OptimistFi, evidence-first equity research. More at optimistfi.com.
iRhythm dokončila akvizici VitalConnect za 237,5 milionu USD v hotovosti a až 423 334 akcií. Transakce rozšiřuje monitorování srdce napříč ambulantní, nemocniční i domácí péčí.
Combination broadens iRhythm’s cardiac monitoring portfolio, advances its multi-vitals strategy and expands iRhythm’s addressable market across the continuum of care.iRhythm’s commercial scale, health system relationships, market access expertise, and integrated clinical service capabilities are expected to accelerate VitalConnect's growth and expand customer access.Transaction is expected to enhance iRhythm's revenue growth rate beginning in 2027 while preserving iRhythm’s previously communicated 15% adjusted EBITDA margin target for 2027. SAN FRANCISCO, Oct. 05, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdings, Inc. (Nasdaq: IRTC) today announced that it completed the previously announced acquisition of Vital Connect, Inc. ("VitalConnect"), a leader in wearable biosensor technology and ambulatory cardiac monitoring.
“Today marks an important milestone as iRhythm continues its evolution toward a broader cardiac monitoring and intelligence platform,” said Quentin Blackford, President and Chief Executive Officer of iRhythm. “VitalConnect brings complementary mobile cardiac telemetry (MCT), multi-vitals and monitoring capabilities to iRhythm’s established end-to-end cardiac monitoring service. Together, we can offer clinicians greater choice, serve more patients and customers across the continuum of care, and deepen customer relationships. We are pleased to welcome the VitalConnect team to iRhythm.”
“Joining iRhythm creates an opportunity to extend the reach and impact of VitalConnect’s technology,” said Peter Van Haur, Chief Executive Officer of VitalConnect. “By bringing together what our team has built with iRhythm’s scale, clinical expertise and customer reach, we believe we can accelerate the growth of our platform, expand access to our technology and create even greater value for clinicians and patients.”
VitalConnect’s cardiac monitoring platform supports multiple modalities, including complementary MCT capabilities. The VitalConnect platform offers differentiated features such as up to 30-day patient monitoring, four-in-one functionality, flexible service models and live look-in. VitalConnect’s platform also has the capability to monitor up to 11 physiological parameters, advancing iRhythm’s multi-vitals strategy beyond traditional ambulatory cardiac monitoring. Together with iRhythm’s end-to-end cardiac monitoring service, the combination creates a broader portfolio designed to serve distinct customer workflows as well as clinician and patient needs.
Strategic Fit and Financial Benefit
The acquisition immediately expands iRhythm's capabilities across ambulatory cardiac monitoring, including MCT, creating a broader portfolio to serve diverse clinical needs. The combination also creates meaningful commercial acceleration opportunities by leveraging iRhythm's scale, customer relationships and go-to-market capabilities.
Further, the addition of VitalConnect broadens iRhythm's addressable market across the continuum of care, extending its reach into inpatient, remote and hospital-to-home settings. The transaction also brings together complementary technology, data and workflow capabilities that are expected to accelerate innovation and enhance customer solutions. Together, these benefits strengthen iRhythm's long-term growth profile and position the company to serve more clinicians, customers and patients across a broader range of care settings.
As previously announced, the acquisition is expected to enhance iRhythm’s revenue growth rate, while preserving its previously communicated adjusted EBITDA margin target of 15% for 2027.
Transaction Detail
The purchase consideration consisted of $237.5 million in cash, subject to customary adjustments, funded from iRhythm's balance sheet and up to 423,334 shares issued in connection with closing. In addition, iRhythm provided $10.0 million of working capital funding to VitalConnect between signing and closing.
iRhythm will provide updated 2026 financial guidance, inclusive of VitalConnect, during its third quarter earnings call on November 5th, 2026.
About iRhythm Holdings, Inc.
iRhythm is a leading digital health care company with a mission to boldly innovate to create trusted solutions that detect, predict, and prevent disease. Combining its Zio® wearable biosensors and cloud-based data analytics with powerful proprietary algorithms, iRhythm distills data from millions of heartbeats into clinically actionable information. Through a relentless focus on patient care, iRhythm's vision is to deliver better data, better insights, and better health for all. For more information, visit www.irhythmtech.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among other things, statements regarding the anticipated strategic, commercial, operational and financial benefits of the transaction; the ability to expand into new markets, care settings, customer categories and commercial partnerships; the potential to take advantage of and accelerate VitalConnect's growth, deepen customer relationships and realize cross-selling opportunities; future product development, regulatory approvals and commercialization; the success of integration and the retention of key employees; the anticipated growth of the mobile cardiac telemetry category; and the expected impact on revenue growth, adjusted EBITDA and adjusted EBITDA margin. These statements may be identified by words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “project,” “should,” “target,” “will” and similar expressions. Forward-looking statements are based on current assumptions and expectations and involve risks and uncertainties that could cause actual results to differ materially, including challenges in integrating VitalConnect and realizing anticipated benefits and synergies on the expected timeline or at all; business disruption or diversion of management’s attention; changes in market demand, reimbursement, competition or regulation; product development or regulatory delays; the loss of key VitalConnect employees, customers or partners; and unforeseen liabilities and future expenditures associated with the transaction; and the risks described under “Risk Factors” and elsewhere in iRhythm's filings with the Securities and Exchange Commission, including its Quarterly Report on Form 10-Q filed on August 6, 2026. These forward-looking statements speak only as of the date of this press release. iRhythm undertakes no obligation to update them except as required by law.
iRhythm ve 2. čtvrtletí 2026 rostl díky inovativním kanálům a partnerstvím v primární péči a populačním zdraví. Firma ale dál čelí tlaku na úhrady v Japonsku, Evropě i USA.
Key Takeaways iRhythm's innovative channels led Q2 growth as primary care and population-health partnerships expanded.iRhythm's AI platform draws on 3B ECG hours, with pilots topping 85% accuracy in arrhythmia detection.iRhythm faces reimbursement pressures in Japan, Europe and the U.S. that could affect adoption and pricing. iRhythm Holdings (IRTC - Free Report) is well-positioned for solid growth over the next few quarters, courtesy of its strong second-quarter 2026 results and structural market expansion. The company’s investments in AI, large-scale ECG data and clinical validation strengthen its competitive moat, while its push into predictive healthcare opens new long-term opportunities. However, reimbursement and regulatory pressures may pose challenges to sustained growth.
Shares of this Zacks Rank #3 (Hold) company have lost 37.8% so far this year against the industry’s 13.5% growth. However, the S&P 500 Index has increased 11.5% in the same timeframe.
iRhythm, a leader in ambulatory cardiac monitoring operating a device-enabled digital diagnostics platform that integrates wearable biosensors (Zio), FDA-cleared AI algorithms and enterprise clinical workflows delivered through EHR systems, has a market capitalization of $3.6 billion. The company’s earnings surpassed estimates in all the trailing four quarters, delivering an average surprise of 1842.7%.
Image Source: Zacks Investment Research
Positive Factors Driving IRTC StockStructural Market Expansion Through Primary Care & Population Health: iRhythm is moving arrhythmia detection upstream from specialists into primary care, value-based care and population health, expanding the settings where long-duration monitoring can be prescribed.
In the second quarter of 2026, innovative channels were the company’s fastest-growing channel, and management said that new partners continued to join across value-based care, primary care and population health. Workflow integration is also deepening. Approximately 60% of second-quarter 2026 volume came from EHR-integrated accounts, up from roughly 53% in the first quarter, and nearly 80 of the top 100 customers were integrated. The company also signed two commercial agreements through its Luum partnership for predictive identification workflows.
AI, Data and Clinical Evidence Create a Durable Competitive Moat: iRhythm's extensive data foundation, built on more than 3 billion hours of curated ECG data and over 12 million patient reports, continues to strengthen its push into predictive cardiac care as the industry shifts toward earlier disease detection. In the second quarter of 2026, the company expanded its collaboration with Desert Oasis Healthcare and secured two commercial agreements through Luum to integrate predictive workflows with cardiac monitoring, while early pilot programs demonstrated more than 85% accuracy in identifying patients with clinically significant arrhythmias before diagnosis.
Meanwhile, the company's productivity initiatives gained momentum following FDA clearance of its third-generation algorithm, which management expects to launch in the first half of 2027. The new algorithm is projected to cut technician review time by up to 50% and generate approximately $100 million in cumulative cost savings over the next five years.
Strong Q2 Results: iRhythm delivered a strong second quarter, delivering solid earnings and revenue growth. The quarter reflected broad-based commercial momentum across cardiology, primary care, innovative channels and international markets. Innovative channels were the fastest-growing area, supported by value-based care, primary care and population-health partnerships.
Approximately 60% of volumes now come from EHR-integrated accounts, while nearly 80 of iRhythm’s top 100 customers are integrated, helping streamline workflows and expand patient access. On the innovation front, iRhythm secured FDA clearance for its third-generation algorithm, which management expects to reduce clinical technician review time by as much as 50% and generate approximately $100 million in cumulative cost savings over five years.
Headwind That May Affect IRTC StockReimbursement and Regulatory Pressures: Despite strong clinical validation, iRhythm continues to face reimbursement-related challenges in international markets. In Japan, Zio is currently reimbursed at rates comparable to traditional Holter monitors, which management considers inadequate and contingent on demonstrating superior clinical outcomes to support future pricing improvements. Similar issues persist in Europe, where reimbursement frameworks are highly fragmented and require extensive negotiations.
In the United States, both Medicare and commercial insurers are focused on cost-effectiveness, which could hinder adoption if budget constraints tighten. The uneven pace of value-based care adoption introduces further uncertainty, as shifts in reimbursement policies may influence testing volumes and pricing.
Estimate TrendiRhythm is witnessing a stable estimate revision trend for 2026. In the past 30 days, the Zacks Consensus Estimate for earnings has remained stable at 60 cents per share.
The Zacks Consensus Estimate for third-quarter 2026 revenues and earnings per share is pegged at $222.3 million and 2 cents, respectively.
Stocks to ConsiderSome better-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) , Veracyte (VCYT - Free Report) and West Pharmaceutical (WST - Free Report) .
Globus Medical, currently carrying a Zacks Rank #2 (Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
Veracyte, currently flaunting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted EPS of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%.
VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 41.8%.
West Pharmaceutical, carrying a Zacks Rank #2 at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.
WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 17.4%.
Key Takeaways iRhythm will acquire VitalConnect for about $287.5 million, with closing expected by the end of 2026.VitalConnect adds MCT, multi-vitals monitoring and up to 30-day patient monitoring to iRhythm's portfolio.The deal is expected to boost iRhythm's revenue growth rate starting in 2027 and broaden its care reach.
iRhythm Holdings,Inc. (IRTC - Free Report) recently announced that it will acquire Vital Connect, Inc., a leader in wearable biosensor technology and ambulatory cardiac monitoring. The transaction is expected to expand iRhythm’s addressable market and accelerate its evolution from ambulatory cardiac monitoring into a broader cardiac monitoring and intelligence platform spanning ambulatory, inpatient and hospital-to-home care.
Per management, the acquisition marks an important milestone in iRhythm’s transition from ambulatory cardiac monitoring to a broader cardiac monitoring and intelligence platform. The addition of VitalConnect’s mobile cardiac telemetry (MCT), multi-vitals and hospital monitoring capabilities complements the Zio platform, expands the company’s patient and customer reach, and creates opportunities to accelerate growth, strengthen customer relationships and serve patients across a wider continuum of care.
Likely Trend of IRTC Stock Following the NewsShares of IRTC have lost 4% since the announcement on Aug. 6. Year to date, shares of the company have declined 30.6% against the industry’s 4.4% growth and the S&P 500’s 13.6% gain.
In the long run, the acquisition of VitalConnect could strengthen iRhythm’s growth prospects by broadening its cardiac monitoring portfolio and expanding its reach across different care settings. The combination of VitalConnect’s monitoring technologies with iRhythm’s established Zio platform and commercial infrastructure could create new revenue opportunities, strengthen relationships with healthcare providers and support wider adoption. The expanded portfolio also positions iRhythm to capture demand across ambulatory, inpatient and remote care markets, supporting its transition toward a more comprehensive cardiac monitoring platform.
IRTC currently has a market capitalization of $4.13 billion.
Image Source: Zacks Investment Research
More on the NewsThe acquisition broadens iRhythm’s cardiac monitoring capabilities by adding VitalConnect’s FDA-cleared platform, which supports multiple monitoring modalities, including MCT, as well as multi-vitals monitoring. VitalConnect offers capabilities including up to 30-day patient monitoring, four-in-one functionality, flexible service models and live look-in.
Together with Zio AT and iRhythm’s planned next-generation MCT offering, the combined portfolio is expected to provide clinicians with greater flexibility across different workflows and care settings. VitalConnect’s biosensor platform can monitor up to 11 physiological parameters, extending iRhythm’s reach into inpatient monitoring, remote patient monitoring and hospital-to-home care.
The transaction also combines complementary technology and expertise. VitalConnect contributes wearable biosensors, AI-enabled algorithms and cloud-based workflows, while iRhythm brings cardiac diagnostic expertise, clinical operations, proprietary algorithms and a scaled commercial platform. The integration could support faster product innovation and enable comprehensive solutions for health systems.
Financial Outlook of AcquisitioniRhythm will acquire VitalConnect for approximately $287.5 million, comprising $237.5 million in cash and approximately $50 million in iRhythm common stock. The company will provide up to $30 million in interim working capital financing to support VitalConnect’s operations before closing. The acquisition is anticipated to close by the end of 2026 and expected to be accretive to iRhythm’s revenue growth rate beginning in 2027.
Industry Prospects Favoring the MarketGoing by the data provided by Mordor Intelligence, the cardiac monitoring market is predicted to be valued at $29.1 billion in 2026 and is expected to witness a CAGR of 5.04% through 2035.
Factors like the rising prevalence of cardiovascular diseases, growing geriatric population, technological advances in wireless & wearable devices, expansion of AI-enabled predictive analytics, reimbursement shift to ambulatory continuous monitoring, as well as increasing awareness and screening programs for heart health, are boosting the market’s growth.
Other NewsiRhythm recently delivered strong second-quarter 2026 results with solid earnings and revenue growth. The quarter reflected broad-based commercial momentum across cardiology, primary care, innovative channels and international markets. Innovative channels were the fastest-growing area, supported by value-based care, primary care and population health partnerships.
The company secured FDA clearance for its third-generation algorithm, expected to reduce technician review time by up to 50% and generate approximately $100 million in cumulative savings over five years. iRhythm is also advancing predictive arrhythmia solutions and expanding its Zio platform.
IRTC’s Zacks Rank & Key PicksIRTC currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) , West Pharmaceutical (WST - Free Report) and The Cooper Companies (COO - Free Report) .
Globus Medical, currently sporting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank stocks here.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
West Pharmaceutical, carrying a Zacks Rank #2 (Buy) at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.
WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 17.4%.
The Cooper Companies, carrying a Zacks Rank #2 at present, reported a second-quarter fiscal 2026 adjusted EPS of $1.21, which beat the Zacks Consensus Estimate by 10%. Revenues of $1.08 billion beat the Zacks Consensus Estimate by 2.6%.
COO has an estimated long-term earnings growth rate of 8.3%. COO’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 5.8%.
iRhythm ve 2. čtvrtletí zvýšil tržby o 20,1 % na 224,2 mil. USD a zúžil provozní ztrátu na 2,5 mil. USD. Zároveň zvedl výhled tržeb na rok 2026 na 880–890 mil. USD.
Key Takeaways iRhythm's Q2 revenues rose 20.1% to $224.2 million, supported by sustained volume demand.Gross margin expanded 160 bps to 72.8%, while the operating loss narrowed to $2.5 million.iRhythm raised 2026 revenue guidance to $880-$890 million and EBITDA margin outlook to 13%-14%. iRhythm Holdings, Inc. (IRTC - Free Report) reported adjusted earnings per share of 58 cents in the second quarter of 2026, against an adjusted loss per share of 32 cents a year ago. The figure beat the Zacks Consensus Estimate by 5900%.
GAAP loss per share for the quarter was 1 cent compared with 44 cents in the year-ago period.
IRTC’s Q2 Revenues in DetailiRhythm registered revenues of $224.2 million in the second quarter, up 20.1% year over year. The increase was primarily driven by sustained volume demand across the customer base, reflecting continued strength in the core business and contributions from newer growth channels. The figure surpassed the Zacks Consensus Estimate by 2.2%.
In the year-to-date period, the company’s shares have declined 27.9% compared with the industry’s loss of 0.8%. The broader S&P 500 Index has increased 13.1% in the same time frame.
Image Source: Zacks Investment Research
IRTC's Revenue Mix Shows Broad-Based GrowthiRhythm derives revenues from the following sources: Contracted third-party payors, Centers for Medicare & Medicaid Services, Healthcare institutions and Non-contracted third-party payors.
Contracted third-party payor revenues totaled $113.8 million in the quarter, up 16.4% year over year. Centers for Medicare & Medicaid Services revenues increased 31.6% to $58.6 million.
Healthcare institutions generated revenues of $37.8 million, up 18.7% from the prior-year quarter. Non-contracted third-party payor revenues rose 11.1% to $14.1 million.
iRhythm's Q2 Margin Expansion Supports ProfitabilityIn the quarter under review, iRhythm’s gross profit increased 22.8% year over year to $163.2 million. Gross margin expanded 160 basis points (bps) to 72.8%, reflecting operational efficiencies, product mix and scale benefits from higher volumes.
Selling, general and administrative expenses increased 4.2% year over year to $131.7 million, while research and development expenses decreased 5.6% to $19.8 million.
Adjusted operating expenses were $145.0 million, down 0.1% year over year despite continued investments in growth initiatives.
The operating loss narrowed to $2.5 million from $18.7 million in the prior-year quarter.
iRhythm’s Financial PositioniRhythm exited second-quarter 2026 with cash and cash equivalents of $246.7 million compared with $240.1 million at the end of first-quarter 2026.
Cumulative net cash provided by operating activities at the end of second-quarter 2026 was $24.9 million compared with $19.8 million a year ago.
IRTC Raises 2026 OutlookiRhythm has increased its outlook for the full year 2026.
IRTC now projects full-year revenues between $880 million and $890 million, up from the prior outlook of $875 million to $885 million. The Zacks Consensus Estimate is pegged at $884.1 million.
The company expects an adjusted EBITDA margin between 13% and 14%, up from 12% to 13% previously.
iRhythm’s Innovation and Growth InitiativesiRhythm delivered a strong second quarter, delivering solid earnings and revenue growth. The quarter reflected broad-based commercial momentum across cardiology, primary care, innovative channels and international markets. Innovative channels were the fastest-growing area, supported by value-based care, primary care and population-health partnerships. Approximately 60% of volumes now come from EHR-integrated accounts, while nearly 80 of iRhythm’s top 100 customers are integrated, helping streamline workflows and expand patient access.
On the innovation front, iRhythm secured FDA clearance for its third-generation algorithm, which management expects to reduce clinical technician review time by as much as 50% and generate approximately $100 million in cumulative cost savings over five years. The company is advancing predictive arrhythmia solutions, with new commercial agreements through its Luum partnership and expanded work with Desert Oasis Healthcare.
iRhythm entered into an agreement to acquire Vital Connect for approximately $287.5 million. The transaction is expected to broaden its cardiac monitoring portfolio across mobile cardiac telemetry, event monitoring, long-term continuous monitoring and short-term Holter, while creating opportunities in inpatient and hospital-to-home monitoring. Alongside continued investments in Zio MCT, primary care, international expansion and adjacent markets such as sleep diagnostics, these initiatives support iRhythm’s strategy of expanding access and evolving into a broader cardiac monitoring and intelligence platform.
IRTC’s Zacks Rank & Key PicksiRhythm currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are West Pharmaceutical (WST - Free Report) , The Cooper Companies (COO - Free Report) and Cardinal Health (CAH - Free Report) , each carrying a Zacks Rank of 2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
West Pharmaceutical reported second-quarter 2026 adjusted earnings per share (EPS) of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.
West Pharmaceutical has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 17.40%.
The Cooper Companies reported a second-quarter fiscal 2026 adjusted EPS of $1.21, which beat the Zacks Consensus Estimate by 10.00%. Revenues of $1.08 billion beat the Zacks Consensus Estimate by 2.6%.
The Cooper Companies has an estimated long-term earnings growth rate of 8.3%. COO’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 5.80%.
Cardinal Health reported a third-quarter fiscal 2026 adjusted EPS of $3.17, which beat the Zacks Consensus Estimate by 13.2%. Revenues of $60.94 billion missed the Zacks Consensus Estimate by 2.3%.
Cardinal Health has an estimated long-term earnings growth rate of 17%. CAH’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 10.27%.
Společnost iRhythm Holdings koupí VitalConnect za zhruba 287,5 milionu USD, aby rozšířila vzdálené monitorování srdce a sledování více vitálních funkcí. Transakce má podpořit růst tržeb a začít přinášet zisk od roku 2027.
Digital healthcare company iRhythm Holdings, Inc. (NASDAQ:IRTC) on Thursday agreed to acquire Vital Connect, Inc., a privately held developer of wearable biosensor technology.
iRhythm Agrees To Acquire VitalConnect for $287.5 MillionThe transaction, valued at approximately $287.5 million, aims to significantly broaden iRhythm’s footprint in ambulatory cardiac monitoring and advanced multi-vitals tracking.
The total purchase price consists of roughly $237.5 million in cash, sourced directly from existing funds on iRhythm’s balance sheet, alongside about $50 million in shares.
To support VitalConnect through the transition, iRhythm will also supply interim working capital financing.
The initial funding starts at $10 million, with additional increments available up to a maximum aggregate of $30 million.
Read Next
Acquisition Broadens Cardiac Monitoring and Multi-Vitals CapabilitiesStrategically, the acquisition integrates VitalConnect’s FDA-cleared technology into iRhythm’s portfolio. This platform features a wide range of cardiac monitoring modalities and multi-vitals tracking capabilities designed for both remote care and hospital settings.
The management expects the buyout to strengthen the company’s long-term growth profile. The integration is projected to become accretive to iRhythm’s overall revenue growth rate beginning in 2027.
The efficiency will help finance future growth investments while maintaining the company’s previously stated adjusted EBITDA margin target of 15% in 2027.
iRhythm reported second quarter adjusted earnings of 58 cents. Sales jumped 20.1% year over year to $224.172 million, beating the consensus of $219.324 million.
The company’s quarterly performance demonstrated robust volume-led revenue growth and expanded margins, with continued momentum across cardiology, primary care, innovative channels, and international markets.
Gross profit was $163.2 million, up 22.8% year over year, while gross margin was 72.8%, a 160-basis point improvement.
The increase in gross profit was primarily due to increased volume of Zio services. The increase in gross margin was primarily driven by continued operational efficiencies, product mix, and scale benefits from higher volumes.
iRhythm Raises Fiscal 2026 Sales GuidanceiRhythm raised its fiscal 2026 sales guidance from $875 million-$885 million to $880 million-$890 million versus the consensus of $881.129 million.
William Blair on Friday wrote, “We expect the company will integrate VitalPatch into the existing Zio Suite software and the company will look to expand using the access to new vitals and other VitalConnect IP.”
“In sum, we think this was a good decision from management as this deal will allow it to further accelerate its top line alongside an eventual MCT launch and bolster its margin profile as the new product ramps up,” analyst Brandon Vazquez wrote.
IRTC Price Action: iRhythm Holdings shares were up 3.68% at $132.84 at the time of publication on Friday, according to Benzinga Pro data.
Read Next
Photo: Shutterstock
Market News and Data brought to you by Benzinga APIs
iRhythm Holdings, Inc. (IRTC - Free Report) came out with quarterly earnings of $0.58 per share, beating the Zacks Consensus Estimate of a loss of $0.01 per share. This compares to a loss of $0.32 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of +5,900.00%. A quarter ago, it was expected that this company would post a loss of $0.56 per share when it actually produced a loss of $0.35, delivering a surprise of +37.5%.
Over the last four quarters, the company has surpassed consensus EPS estimates four times.
IRHYTHM HLDGS, which belongs to the Zacks Medical Info Systems industry, posted revenues of $224.17 million for the quarter ended June 2026, surpassing the Zacks Consensus Estimate by 2.18%. This compares to year-ago revenues of $186.69 million. The company has topped consensus revenue estimates four times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
IRHYTHM HLDGS shares have lost about 29.8% since the beginning of the year versus the S&P 500's gain of 12.8%.
What's Next for IRHYTHM HLDGS?While IRHYTHM HLDGS has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for IRHYTHM HLDGS was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.03 on $220.97 million in revenues for the coming quarter and $0.13 on $881.52 million in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical Info Systems is currently in the top 28% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Another stock from the broader Zacks Medical sector, Outlook Therapeutics, Inc. (OTLK - Free Report) , has yet to report results for the quarter ended June 2026.
This company is expected to post quarterly loss of $0.09 per share in its upcoming report, which represents a year-over-year change of +79.6%. The consensus EPS estimate for the quarter has been revised 12.5% higher over the last 30 days to the current level.
Outlook Therapeutics, Inc.'s revenues are expected to be $1.2 million, down 20% from the year-ago quarter.
iRhythm Technologies zvýšila celoroční výhled tržeb na 880 až 890 milionů USD a upravené EBITDA marže na 13 % až 14 %. Ve 2. čtvrtletí tržby vzrostly o 20,1 % na 224,2 milionu USD.
Top 3 Robotics and Automation Stocks for the Next AI BoomiRhythm Technologies NASDAQ: IRTC reported second-quarter revenue growth of 20.1% and raised its full-year outlook, while announcing an agreement to acquire VitalConnect to broaden its cardiac monitoring portfolio and enter additional patient-monitoring markets.
Get iRhythm Technologies alerts:
Revenue for the quarter ended at $224.2 million, marking iRhythm’s seventh consecutive quarter of growth above 20%, President and Chief Executive Officer Quentin Blackford said. Growth was supported by demand for the company’s Zio ambulatory cardiac-monitoring services across cardiology, primary care, innovative channels and international markets.
4 Stocks With Huge Cash Holdings at Silicon Valley Bank“Volume remained the primary driver of growth,” Chief Financial Officer Dan Wilson said, adding that modest pricing gains and collections execution also supported the quarter. New accounts contributed about 45% of year-over-year volume growth, while the company said several large accounts added in early 2025 have transitioned into its same-store growth category.
Profitability Improves as Revenue Grows Second-quarter gross margin increased 160 basis points year over year to 72.8%, driven by manufacturing automation, workflow improvements, product mix and scale benefits, Wilson said. Adjusted operating expenses were essentially flat at $145 million, compared with $145.2 million in the prior-year period.
The company reported a GAAP net loss of $0.4 million, or $0.01 per diluted share, compared with a GAAP net loss of $14.2 million, or $0.44 per diluted share, a year earlier. Adjusted net income was $19.3 million, or $0.58 per diluted share, compared with an adjusted net loss of $10.2 million, or $0.32 per diluted share, in the second quarter of 2025.
Adjusted EBITDA reached $43.3 million, or 19.3% of revenue, improving by more than 1,000 basis points from the prior-year period. Free cash flow was positive $37.5 million, which Wilson described as a company record. iRhythm ended the quarter with $591.3 million in cash equivalents and marketable securities.
Second-quarter revenue: $224.2 million, up 20.1% year over year. Gross margin: 72.8%, up 160 basis points year over year. Adjusted EBITDA: $43.3 million, or 19.3% of revenue. Free cash flow: $37.5 million. Cash equivalents and marketable securities: $591.3 million. VitalConnect Deal Expands Monitoring Portfolio Blackford said VitalConnect would add a platform spanning mobile cardiac telemetry, or MCT, event monitoring, long-term continuous monitoring and short-term Holter monitoring. Its technology is also FDA-cleared for continuous patient monitoring in hospitals.
VitalConnect’s biosensor can measure up to 11 physiological parameters, including ECG, heart rate, respiratory rate and body temperature. The company said the technology could support future opportunities in inpatient monitoring, hospital-to-home programs and remote patient monitoring.
iRhythm expects VitalConnect to contribute positively to revenue growth beginning in 2027. Wilson said VitalConnect is currently operating at an approximately $65 million annual revenue run rate based on iRhythm’s revenue-recognition approach. The company expects the combined business to maintain gross margin above 70% and said it remains confident in reaching its prior target of a 15% adjusted EBITDA margin in 2027.
The transaction is expected to close by the end of 2026, subject to review. Blackford characterized it as pro-competitive, noting that the MCT market includes competitors such as BioTel and Preventice. He said iRhythm expects to prioritize integration of VitalConnect’s VitalPatch product into its national commercial organization in early 2027.
Management said it intends to maintain a multi-product MCT strategy. Zio AT, Zio MCT and VitalPatch address different physician, patient and workflow preferences, according to Blackford. While the company remains focused on obtaining FDA clearance for Zio MCT during the first half of 2027, VitalPatch will be the near-term priority for commercial integration if the acquisition closes as anticipated.
Wilson said the deal includes $50 million in equity, calculated using a 30-day volume-weighted average price, equating to a little more than 420,000 shares and less than 1.5% dilution.
Primary Care, AI and International Initiatives iRhythm continued to target earlier identification of arrhythmias through primary care, value-based care and population-health settings. Blackford said the company estimates that at least 27 million people in the United States are at risk for arrhythmias, with many first entering the healthcare system through primary care.
During the quarter, iRhythm signed two commercial agreements through its partnership with Lucem to combine predictive identification workflows with iRhythm monitoring. It also expanded work with Desert Oasis Healthcare using AI-driven analytics to identify patients who may benefit from cardiac evaluation and monitoring.
The innovative channel was iRhythm’s fastest-growing channel during the quarter. Early pilot programs have demonstrated more than 85% accuracy in identifying patients with clinically relevant arrhythmias before they enter the diagnostic process, Blackford said. The company also began direct-to-patient educational initiatives through the PatientPoint network and said it expects to continue investing in those efforts during the second half of the year.
Approximately 60% of iRhythm’s volume now comes from EHR-integrated accounts, with nearly 80 of its top 100 customers integrated, Blackford said. Internationally, the company cited progress with the U.K.’s National Health Service, relationships with key opinion leaders in the Netherlands, and a higher reimbursement rate in Japan that took effect June 1.
Regulatory Updates and Raised Outlook iRhythm said final local coverage determinations issued by Noridian, CGS and Palmetto clarified modality-specific coverage without adding access restrictions. Wilson also said preliminary CMS physician-fee-schedule proposals indicated reimbursement rate increases in the low-single-digit percentages for long-term continuous monitoring and MCT.
The company received FDA clearance for its third-generation algorithm, which it plans to launch across its platform in the first half of 2027. Blackford said the algorithm is expected to reduce clinical technician review time by as much as 50% and generate approximately $100 million in cumulative cost savings over five years.
iRhythm remains subject to an FDA warning letter. Blackford said the company has updated the agency on completed remediation activities and a self-initiated third-party audit, while awaiting the FDA’s further review.
The company also disclosed that it settled outstanding litigation with Baxter and its subsidiaries, Welch Allyn and Bardy Diagnostics, on July 31 for a $50 million payment. Separately, iRhythm said a June cybersecurity incident involving certain third-party-hosted business applications was contained and did not materially affect products, patient care, operations or financial results.
For 2026, iRhythm raised revenue guidance to $880 million to $890 million, representing growth of 18% to 19%. Third-quarter revenue is expected to range from $221 million to $223 million. The company increased its full-year adjusted EBITDA margin outlook to 13% to 14%, while projecting a third-quarter adjusted EBITDA margin of 12% to 13%.
About iRhythm Technologies (NASDAQ:IRTC)iRhythm Technologies, Inc is a medical technology company that develops and commercializes wearable cardiac monitoring devices and associated data analytics services. Founded in 2006 and headquartered in San Francisco, California, the company's flagship product is the Zio® patch, a discreet, single-use, continuous ECG recorder designed to monitor heart rhythms for up to 14 days. iRhythm's digital diagnostics platform combines biosensor technology with proprietary algorithms to detect arrhythmias and streamline data interpretation for physicians.
The Zio service is prescribed by cardiologists and other healthcare providers to aid in the diagnosis of atrial fibrillation, bradycardia, tachycardia and other rhythm disorders.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Should You Invest $1,000 in iRhythm Technologies Right Now?Before you consider iRhythm Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and iRhythm Technologies wasn't on the list.
While iRhythm Technologies currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.
